![Mark J. Bamberger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark J. Bamberger
No open positions remaining
Profile
Mark J.
Bamberger worked as the Director of Cardiovascular Disease Research at Pfizer Inc. from 2004 to 2008.
He also served as the Chief Scientific Officer at Stealth BioTherapeutics Corp.
from 2014 to 2020.
Bamberger received his undergraduate degree from St. Joseph's University in 1974 and his doctorate from Drexel University College of Medicine.
Former positions of Mark J. Bamberger
| Companies | Position | End |
|---|---|---|
| STEALTH BIOTHERAPEUTICS CORP | Chief Tech/Sci/R&D Officer | 2019-12-31 |
| PFIZER INC. | Corporate Officer/Principal | 2007-12-31 |
Training of Mark J. Bamberger
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
86
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
St. Joseph's University
 St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Drexel University College of Medicine
 Drexel University College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stealth BioTherapeutics Corp.
 Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops investigational drugs for the treatment of diseases involving mitochondrial dysfunction | Health Technology |
- Stock Market
- Insiders
- Mark J. Bamberger
